香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：8223） 有關獨立非執行董事變動之 補充公告 胡先生確認：(i)就 GEM 上市規則第 5.09 條項下的獨立性準則而言，彼乃屬獨立；(ii)彼於過去或現 時概無於本公司或其附屬公司的業務中擁有財務或其他權益，與本公司任何核心關連人士（定義見 GEM 上市規則）亦無任何關連；及(iii)於其獲委任時，概無其他因素可影響其獨立性。經提名委員會 建議，董事會認為胡先生乃屬獨立，並符合 GEM 上市規則第 5.09 條項下的所有獨立性準則。 於本公告日期，胡先生並無於本公司及╱或其相聯法團（定義見證券及期貨條例第 XV 部）的任何 股份、相關股份或債券中擁有任何權益。 承董事會命 紫元元集團控股有限公司 主席兼行政總裁 張俊深先生 香港，二零二六年一月二日 於本公告日期， ...

Core Viewpoint - Ziyuan Yuan (08223.HK) announced the resignation of independent non-executive director Zhou Zhaoheng, effective December 29, 2025, due to his need to devote more time and energy to other work [1] - Concurrently, Hu Tao has been appointed as the independent non-executive director, effective December 29, 2025 [1] Summary by Category - **Director Changes** - Zhou Zhaoheng resigns as independent non-executive director effective December 29, 2025 [1] - Hu Tao appointed as independent non-executive director effective December 29, 2025 [1]

Group 1 - The company announced that Mr. Zhou Zhaoheng has resigned as an independent non-executive director due to the need to devote more time and energy to other work, effective from December 29, 2025 [1] - Mr. Hu Tao has been appointed as the independent non-executive director, also effective from December 29, 2025 [1]

Group 1 - The company announced that Mr. Zhou Zhaoheng has resigned as an independent non-executive director due to the need to devote more time and energy to other work, effective from December 29, 2025 [1] - Mr. Hu Tao has been appointed as the independent non-executive director, also effective from December 29, 2025 [1]

非執行董事 Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：8223） 董事名單與其角色及職能 紫元元控股集團有限公司（「本公司」）董事（「董事」）會（「董事會」）成員載列如下。 執行董事 張俊深先生 （主席兼行政總裁） 田志威先生 呂迪先生 李新培女士 獨立非執行董事 陳志峰先生 鄧斌博士 胡涛先生 董事會設有三個委員會。下表提供各董事會成員在該等委員會中所擔任的職位。 | | 董事會委員會 | | | | | --- | --- | --- | --- | --- | | 董事 | | 審核委員會 | 薪酬委員會 | 提名委員會 | | 張俊深先生 | | － | － | 主席 | | 田志威先生 | | － | 成員 | － | | 呂迪先生 | | 成員 | － | － | | 陳志峰先生 | | 主席 | 成員 | 成員 | | 鄧斌博士 | | 成員 | 主席 | 成員 | 香港，二零二五年十二月二十九日 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：8223） 獨立非執行董事之變動 獨立非執行董事辭任 紫元元控股集團有限公司（「本公司」，連同其附屬公司，統稱為「本集團」）董事（「董事」） 會（「董事會」）謹此宣佈, 周兆恒先生（「周先生」）因需投入更多時間及精力於其他工作，已 辭任本公司獨立非執行董事，自二零二五年十二月二十九日起生效。 周先生已確認，彼與董事會之間並無意見分歧，亦無任何有關彼辭任之事宜須敦請香港聯合交易 所有限公司（「聯交所」）或本公司股東垂注。 董事會謹藉此機會鳴謝周先生任內為本公司作出之貢獻。 委任獨立非執行董事 董事會欣然宣佈胡濤先生（「胡先生」）獲委任為本公司獨立非執行董事，自二零二五年十二月 二十九日起生效。 有關胡先生之履歷詳情如下： 胡先生已於二零一七年畢業於清華大學五道口金融學院 ...

Market Overview - The Hong Kong stock market opened slightly higher on December 24, with the Hang Seng Index rising 0.02% to 25,780.09 points, the Hang Seng Tech Index up 0.07% to 5,492.83 points, the National Enterprises Index increasing by 0.09% to 8,922.07 points, and the Red Chip Index gaining 0.19% to 4,075.35 points [1] Company News - Pacific Basin Shipping (02343.HK) plans to acquire four newly built small handy bulk carriers for USD 119 million [2] - Xinyi Energy (03868.HK) intends to acquire 100% equity of Jinzhai Xinyi Wind Power for HKD 62 million [3] - Tianjin Port Development (03382.HK) proposes to sell 60% equity of China Railway Storage and Transportation for HKD 22.52 million, primarily engaged in coal sales [4] - Shandong Xinhua Pharmaceutical (00719.HK) has received a drug registration certificate for its Oseltamivir phosphate dry suspension [5] - Yiyuan Yuan (08223.HK) has entered into a strategic cooperation framework agreement with Pengfeng Technology to explore digital transformation opportunities in the traditional Chinese medicine industry [5] - Yihua Tong (02402.HK) completed a placement of 8.88 million shares, raising HKD 198 million, primarily for repaying bank loans [7] - Runge Interactive (02422.HK) plans to place up to 160 million shares at a discount of approximately 19.44%, raising about HKD 68.6 million [8] - Tencent Holdings (00700.HK) repurchased 1.051 million shares for HKD 636 million at prices between HKD 602.5 and HKD 613.5 [9] - Kuaishou-W (01024.HK) repurchased 2.7176 million shares for HKD 174 million at prices between HKD 63.7 and HKD 64.65 [10] - Xiaomi Group-W (01810.HK) repurchased 3.75 million shares for HKD 147 million at prices between HKD 39.1 and HKD 39.28 [11] - COSCO Shipping Holdings (01919.HK) repurchased approximately HKD 65.48 million worth of shares, totaling 4.7215 million shares at prices between HKD 13.75 and HKD 13.93 [12] - Huaxin Cement (06655.HK) shareholder Huaxin Group plans to increase its holdings in the company's A-shares by HKD 200 million to HKD 400 million [13] Institutional Insights - Dongwu Securities suggests that while there may be short-term opportunities in the Hong Kong market, it is advisable to maintain a cautious stance. The current position is seen as attractive for medium to long-term allocation, with potential for a "Christmas rally" in US tech stocks that could resonate with Hong Kong tech stocks, although there are concerns about stock unlocks affecting the market [14] - Founder Securities highlights strong demand for energy storage, benefiting both power batteries and energy storage batteries, with expected growth rates of over 15% and 40% respectively by 2026. The lithium market is also expected to see a gradual recovery in supply-demand dynamics, with prices likely to rise [14] - CICC forecasts that global tungsten production will increase from 82,800 tons in 2025 to 89,900 tons by 2028, while demand will rise from 102,100 tons to 110,000 tons, indicating a persistent supply-demand gap. The demand for tungsten-based new materials is expected to grow due to advancements in manufacturing and new applications [15]

Core Viewpoint - The company has entered into a strategic cooperation framework agreement with Shenzhen Qianhai Pengfeng Industrial Technology Co., Ltd. to explore opportunities in the digital transformation of the traditional Chinese medicine industry and asset value enhancement [1] Group 1: Strategic Cooperation - The agreement aims to establish a long-term strategic partnership focusing on the digital upgrade and platform operation of the traditional Chinese medicine industry [1] - The collaboration will involve technical and business cooperation related to the digitalization of physical assets [1] - Both parties will work together to expand the domestic and international markets for traditional Chinese medicine and related products [1] - The agreement includes discussions on multi-level capital cooperation, including equity investment [1] Group 2: Business Impact - The board believes that this strategic cooperation will extend and apply the company's capabilities in physical asset management and supply chain services without altering its existing main business [1] - The partnership aims to explore digital management and platform operation models in the field of traditional Chinese medicine and related physical assets, enhancing asset management efficiency and supply chain transparency [1] - By leveraging synergies in technology, platforms, and market resources with the partner, the company can further expand its business scenarios in the related industry chain, enhancing its overall competitiveness in the healthcare and related supply chain service sectors, ultimately creating long-term value for shareholders [1]

Company News - Pacific Shipping (02343.HK) plans to acquire four newly built small handy bulk carriers for USD 119 million [2] - Xinyi Energy (03868.HK) intends to acquire 100% equity of Jinzhai Xinyi Wind Power for HKD 62 million [2] - Tianjin Port Development (03382.HK) proposes to sell 60% equity of China Railway Storage and Transportation for HKD 22.5243 million, primarily engaged in coal sales [2] - Valiant Bio-B (09887.HK) announced the successful administration of LBL-024, a PD-L1/4-1BB bispecific antibody, to the first patient in the Phase Ib/II clinical trial for platinum-resistant ovarian cancer [2] - Shandong Xinhua Pharmaceutical (00719.HK) has received a drug registration certificate for its Oseltamivir phosphate dry suspension [2] - Ziyuan Yuan (08223.HK) signed a strategic cooperation framework agreement with Pengfeng Technology to explore digital transformation and asset value enhancement in the traditional Chinese medicine industry [2] - Jiaxing Gas (09908) terminated its agreement with concerted action persons [2] Financing and Buyback Activities - Yihua Tong (02402.HK) completed a placement of 8.88 million shares, raising HKD 198 million, primarily for repaying bank loans [2] - Rungao Interactive (02422.HK) plans to place up to 160 million shares at a discount of approximately 19.44%, aiming to raise about HKD 68.6 million [2] - Tencent Holdings (00700.HK) repurchased 1.051 million shares for HKD 636 million, with prices ranging from HKD 602.5 to 613.5 [3] - Kuaishou-W (01024.HK) repurchased 2.7176 million shares for HKD 174 million, with prices between HKD 63.7 and 64.65 [3] - Xiaomi Group-W (01810.HK) repurchased 3.75 million shares for HKD 147 million, with prices from HKD 39.1 to 39.28 [4] - COSCO Shipping Holdings (01919) announced a repurchase of 4.7215 million shares for approximately HKD 65.4829 million [4] - Huaxin Cement (06655.HK) major shareholder Huaxin Group plans to increase its holdings in the company's A-shares by HKD 200 million to 400 million [4]

Core Viewpoint - The company has entered into a strategic cooperation framework agreement with Shenzhen Qianhai Pengfeng Industrial Technology Co., Ltd. to explore opportunities in the digital transformation and asset value enhancement of the traditional Chinese medicine industry [1] Group 1: Strategic Cooperation - The agreement aims to establish a long-term strategic partnership focusing on the digital upgrade and platform operation of the traditional Chinese medicine industry [1] - Key areas of collaboration include digitalization of physical assets, joint market expansion for traditional Chinese medicine and related products, and exploring multi-level capital cooperation including equity investment [1] Group 2: Business Operations and Expertise - The company primarily engages in financing leasing services for medical equipment, maternal and infant care services, and trade of medical devices and consumables in China [1] - The board believes that this strategic cooperation will enhance the company's capabilities in asset management and supply chain services without altering its existing core business [1] - The collaboration is expected to improve asset management efficiency and supply chain transparency in the field of traditional Chinese medicine [1] Group 3: Long-term Value Creation - Through synergy in technology, platforms, and market resources with the partner, the company aims to expand its business landscape in the healthcare and related supply chain service sectors [2] - The board considers the terms of the framework agreement to be fair and reasonable, aligning with the overall interests of the company and its shareholders [2]